Federico Innocenti

15.8k total citations · 2 hit papers
211 papers, 7.8k citations indexed

About

Federico Innocenti is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Federico Innocenti has authored 211 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Oncology, 101 papers in Molecular Biology and 45 papers in Cancer Research. Recurrent topics in Federico Innocenti's work include Cancer therapeutics and mechanisms (59 papers), Colorectal Cancer Treatments and Studies (55 papers) and Pharmacogenetics and Drug Metabolism (33 papers). Federico Innocenti is often cited by papers focused on Cancer therapeutics and mechanisms (59 papers), Colorectal Cancer Treatments and Studies (55 papers) and Pharmacogenetics and Drug Metabolism (33 papers). Federico Innocenti collaborates with scholars based in United States, Italy and Japan. Federico Innocenti's co-authors include Mark J. Ratain, Jacqueline Ramı́rez, Donna Niedzwiecki, Soma Das, Richard M. Goldberg, Robert J. Mayer, Lalitha Iyer, Richard L. Schilsky, Heinz‐Josef Lenz and Alan P. Venook and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Federico Innocenti

204 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

2004 695 citations Federico Innocenti, Soma Das et al. Journal of Clinical Oncology profile →
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

2010 679 citations Donna Niedzwiecki, Federico Innocenti et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Federico Innocenti

Since Specialization

Citations

This map shows the geographic impact of Federico Innocenti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Innocenti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Innocenti more than expected).

Fields of papers citing papers by Federico Innocenti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Innocenti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Innocenti. The network helps show where Federico Innocenti may publish in the future.

Co-authorship network of co-authors of Federico Innocenti

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Innocenti. A scholar is included among the top collaborators of Federico Innocenti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Innocenti. Federico Innocenti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genetic effects on chromatin accessibility uncover mechanisms of liver gene regulation and quantitative traits 2025 ·Genome Research ·(unknown), Hannah J. Perrin, (unknown), (unknown), Swarooparani Vadlamudi, (unknown), Amy S. Etheridge, K. Alaine Broadaway, Jonathan D. Rosen, Arushi Varshney, Amarjit S. Chaudhry, Paul J. Gallins, Fred A. Wright, Yi‐Hui Zhou, Stephen C.J. Parker, Laura M. Raffield, Erin G. Schuetz, Federico Innocenti, Karen L. Mohlke	0
2	Gatekeeping in primary care: Analysing GP referral patterns and specialist consultations in the NHS 2024 ·Economic Modelling ·Federico Innocenti, Barry McCormick, Catia Nicodemo	1
3	Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension 2024 ·The Pharmacogenomics Journal ·Júlia C.F. Quintanilha, William Kevin Kelly, Federico Innocenti	1
4	Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients 2023 ·The Pharmacogenomics Journal ·Nancy Gillis, Amy S. Etheridge, (unknown), D. Neil Hayes, Michele C. Hayward, J. Todd Auman, Joel S. Parker, Federico Innocenti	2
5	DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations 2023 ·Journal of Clinical Oncology ·Federico Innocenti, (unknown), Xueping Qu, Fang‐Shu Ou, Omar Kabbarah, Charles D. Blanke, Alan P. Venook, Heinz‐Josef Lenz, Naim U. Rashid	5
6	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer 2022 ·Nature Communications ·Radia Marie Johnson, Xueping Qu, (unknown), Ling‐Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang‐Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, (unknown), Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz‐Josef Lenz, Carlos Bais	24
7	Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance) 2022 ·Journal of Clinical Oncology ·Kanwal Raghav, Fang‐Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz‐Josef Lenz, Scott Kopetz	25
8	All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide 2021 ·JCO Oncology Practice ·(unknown), Federico Innocenti	40
9	PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors 2021 ·The Pharmacogenomics Journal ·Júlia C.F. Quintanilha, Alessandro Racioppi, Jin Wang, Amy S. Etheridge, (unknown), Carol E. Peña, Andrew D. Skol, Daniel J. Crona, D. Y. Lin, Federico Innocenti	6
10	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) 2020 ·Clinical Cancer Research ·Federico Innocenti, Alexander B. Sibley, (unknown), Amy S. Etheridge, Chen Jiang, Fang‐Shu Ou, (unknown), Sarah J. Plummer, Graham Casey, Monica M. Bertagnolli, Howard L. McLeod, J. Todd Auman, Charles D. Blanke, Yoichi Furukawa, Alan P. Venook, Michiaki Kubo, Heinz‐Josef Lenz, Joel S. Parker, Mark J. Ratain, Kouros Owzar	13
11	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib 2020 ·Molecular Cancer Therapeutics ·Yingmiao Liu, Jing Lyu, Kirsten B. Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, (unknown), Federica Marmorino, Daniele Rossini, Richard M. Goldberg, Alfredo Falcone, Chiara Cremolini, Kouros Owzar, Anastasia Ivanova, Dominic T. Moore, Michael S. Lee, Hanna K. Sanoff, Federico Innocenti, Andrew B. Nixon	15
12	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405 2020 ·JNCI Cancer Spectrum ·Brendan J. Guercio, Sui Zhang, Alan P. Venook, Fang‐Shu Ou, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, (unknown), Bert H. O’Neil, James E. Shaw, Blasé N. Polite, Howard S. Höchster, James N. Atkins, Richard M. Goldberg, Justin C. Brown, Eileen M. O’Reilly, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt	8
13	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients 2020 ·The AAPS Journal ·(unknown), Amy S. Etheridge, Eleftheria Tsakalozou, Jacqueline Ramı́rez, Erika Cecchin, Ron H. N. van Schaik, Giuseppe Toffoli, Mark J. Ratain, Ron H.J. Mathijssen, Alan Forrest, Robert R. Bies, Federico Innocenti	4
14	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance) 2019 ·Clinical Cancer Research ·Chen Yuan, Kaori Sato, Bruce W. Hollis, Sui Zhang, Donna Niedzwiecki, Fang‐Shu Ou, (unknown), Bert H. O’Neil, Federico Innocenti, Heinz‐Josef Lenz, Charles D. Blanke, Richard M. Goldberg, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kimmie Ng	44
15	Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer 2016 ·Clinical Cancer Research ·Giuseppe Toffoli, Manish Sharma, Elena Marangon, Bianca Posocco, Elizabeth Gray, Quan Mai, Angela Buonadonna, Blasé N. Polite, Gianmaria Miolo, (unknown), Federico Innocenti	31
16	Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer 2011 ·Clinical Cancer Research ·Dylan M. Glubb, Elisa Cerri, (unknown), Wei Zhang, Osman Mirza, Emma E. Thompson, Peixian Chen, Soma Das, Jacek Jassem, Witold Rzyman, Mark W. Lingen, Ravi Salgia, Fred R. Hirsch, Rafał Dziadziuszko, Kurt Ballmer‐Hofer, Federico Innocenti	65
17	Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue 2011 ·PLoS Genetics ·Federico Innocenti, Gregory M. Cooper, Ian B. Stanaway, Eric R. Gamazon, Joshua D. Smith, Snezana Mirkov, Jacqueline Ramı́rez, Wanqing Liu, Yvonne S. Lin, (unknown), (unknown), Nathan D. Trinklein, Erin G. Schuetz, Deborah A. Nickerson, Ken Thummel, Mark J. Rieder, Allan E. Rettie, Mark J. Ratain, Nancy J. Cox, Christopher D. Brown	134
18	UGT1A1 genotyping in patients undergoing treatment with irinotecan. 2005 ·PubMed ·Federico Innocenti	11
19	Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. 2003 ·PubMed ·Federico Innocenti, Mark J. Ratain	39
20	Correspondence re: Raida, M. et al., Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)-related Toxicity Compared with Controls. Clin. Cancer Res., 7: 2832-2839, 2001. 2002 ·Clinical Cancer Research ·Federico Innocenti, Mark J. Ratain	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact